<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="146254">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT01851486</url>
  </required_header>
  <id_info>
    <org_study_id>0393-12-RMB.CTIL</org_study_id>
    <nct_id>NCT01851486</nct_id>
  </id_info>
  <brief_title>The Relationships Between the Noradrenergic, Opioid and Pain System</brief_title>
  <sponsors>
    <lead_sponsor>
      <agency>Rambam Health Care Campus</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Rambam Health Care Campus</source>
  <oversight_info>
    <authority>Israel: Ministry of Health</authority>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The role of alpha2 receptor agonist on pain perception and modulation will be examined. In
      addition whether this is mediated through the opioid system will be examined. Pain
      perception and modulation will be examined before and after administration of Clonidine or
      placebo together with Naloxone or saline.
    </textblock>
  </brief_summary>
  <overall_status>Not yet recruiting</overall_status>
  <start_date>May 2013</start_date>
  <completion_date type="Anticipated">January 2015</completion_date>
  <primary_completion_date type="Anticipated">January 2014</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <study_design>Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Basic Science</study_design>
  <primary_outcome>
    <measure>The changes in pain responses after administration of alpha 2 agonist and mu receptor antagonist</measure>
    <time_frame>2 years</time_frame>
    <safety_issue>No</safety_issue>
    <description>The change in pain perception (pain thresholds and pain ratings of suprathresholds stimuli) and in the excitatory and inhibitory pain modulation responses (assessed by the temporal summation and conditioned pain modulation paradigms) will be examined before and after administration of alpha 2 agonist with  and without mu receptor antagonist</description>
  </primary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Anticipated">80</enrollment>
  <condition>Experimental Pain Perception</condition>
  <arm_group>
    <arm_group_label>Clonidine+ Saline</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Clonidine 0.15 mg and saline 0.15 mg/kg</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Clonidine + Naloxone</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Clonidine 0.15 mg and Naloxone 0.15 mg/kg</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo +Naloxone</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Placebo 0.15 mg+ naloxone 0.15 mg/kg</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo +saline</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Placebo 0.15 mg+ saline 0.15 mg/kg</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Clonidine</intervention_name>
    <description>Clonidine 0.15 mg</description>
    <arm_group_label>Clonidine+ Saline</arm_group_label>
    <arm_group_label>Clonidine + Naloxone</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Naloxone</intervention_name>
    <description>naloxone 0.15 mg/kg</description>
    <arm_group_label>Clonidine + Naloxone</arm_group_label>
    <arm_group_label>Placebo +Naloxone</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>placebo</intervention_name>
    <arm_group_label>Placebo +Naloxone</arm_group_label>
    <arm_group_label>Placebo +saline</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>saline</intervention_name>
    <arm_group_label>Clonidine+ Saline</arm_group_label>
    <arm_group_label>Placebo +saline</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Healthy volunteers

          -  Age 18-40

          -  No chronic disease

        Exclusion Criteria:

          -  Subjects who suffer from chronic pain / pain syndrome

          -  use of anti-depressant or anti-psychotic drugs

          -  suffering from cardiovascular disease

          -  breast feeding
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>40 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>David Yarnitsky, Prof.</last_name>
    <email>d_yarnitsky@rambam.health.gov.il</email>
  </overall_contact>
  <location>
    <facility>
      <name>Rambam Health Care Campus</name>
      <address>
        <city>Haifa</city>
        <country>Israel</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>David Yarnitsky</last_name>
      <email>d_yarnitsky@rambam.health.gov.il</email>
    </contact>
  </location>
  <location_countries>
    <country>Israel</country>
  </location_countries>
  <verification_date>May 2013</verification_date>
  <lastchanged_date>May 9, 2013</lastchanged_date>
  <firstreceived_date>May 2, 2013</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Rambam Health Care Campus</investigator_affiliation>
    <investigator_full_name>d_yarnitsky</investigator_full_name>
    <investigator_title>Professor, Head on Neurology Department</investigator_title>
  </responsible_party>
  <is_fda_regulated>No</is_fda_regulated>
  <has_expanded_access>No</has_expanded_access>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Clonidine</mesh_term>
    <mesh_term>Naloxone</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
